Same-day dispatch on orders by 2 PM ETFree shipping over $150Save up to 50% with volume pricing
0
  1. Home
  2. Shop
  3. Tissue + immune
  4. ARA-290
ARA-290 10 mg research vial

Tissue + immune · EPO helix-B surface derived 11-amino-acid peptide

ARA-290

10 mg · 11 residues · 1257.3 Da

$60.00per vial

Size$6.00/mg

10 mg Lyophilised · sealed vial

Quantity10+ of one compound: 40% off

Choose a quantity
1

Same-day dispatch on orders by 2 PM ET, Monday to Friday

Arrives in 2 business days, tracked

Free shipping over $150

Earn Research Credit on top of your discount. VIP earns 3x more.
  • 7 tests, every lotIndependent lab
  • 2 Day ShippingFrom the USA, tracked
  • Encrypted checkoutSSL secured
  • PassedSterility & endotoxin
  • PassedIdentity & purity, 99.47%

For in-vitro research use only. Not for human or animal use.

Researchers also add

01Verified test results

Every lot, independently tested.

ARA-290 lot SA-ARA-2610 was tested Oct 8, 2026 at an independent laboratory before it shipped. Every value is printed against its limit, so a pass means something.

Independent labIndependent third-party laboratorySample data

Certificate of analysis

99.47%

Purity by HPLC

Profile drawn from the reported purity

Lot
SA-ARA-2610
Tested
Oct 8, 2026
Labelled
10 mg
Measured
10.23 mg
7 of 7 within limitsQR on every label
Full release panel7 passed · 0 flagged
  • PurityHPLC · limit ≥ 99.0%99.47%Pass
  • IdentityMass spectrometry · limit 1257.3 ± 1.0 Da1257.3 DaPass
  • Net contentQuantitative HPLC · limit ≥ 10 mg10.23 mgPass
  • EndotoxinLAL assay · limit ≤ 0.5 EU/mg0.08 EU/mgPass
  • SterilityMembrane filtration · limit No growthNo growthPass
  • Heavy metalsICP-MS · limit ≤ 10 ppm total0.7 ppmPass
  • MoistureKarl Fischer · limit ≤ 8.0%3.1%Pass

Purity by HPLC, identity by mass spectrometry, net content by quantitative HPLC, endotoxin by LAL, sterility by membrane filtration, heavy metals by ICP-MS and moisture by Karl Fischer. Report SA-ARA-2610-01, Oct 8, 2026. Open the lot record.

Every lot on record

Open any lot's certificate. Your order ships from the current released lot, and its QR code opens this record.

All 2 ARA-290 lots
Latest
ARA-290 10 mgLot SA-ARA-2610

99.47%

HPLC purity

Labelled10 mgMeasured10.23 mg+2.3%
  • IdentityConfirmed
  • EndotoxinPass
  • SterilityNo growth
  • Heavy metalsPass

Tested Oct 8, 2026 · 7/7 assays · sample

ARA-290 10 mgLot SA-ARA-2609

99.20%

HPLC purity

Labelled10 mgMeasured10.20 mg+2.0%
  • IdentityConfirmed
  • EndotoxinPass
  • SterilityNo growth
  • Heavy metalsPass

Tested Sep 10, 2026 · 7/7 assays · sample

02Verify your vial

Three steps from label to lab.

  1. 01Scan the label

    Every vial label carries a QR code. Point your phone camera at it.

  2. 02Land on its record

    The code opens that lot's certificate with every assay value. No phone? Type the lot from your packing slip on Verify a lot.

  3. 03Check it with the lab

    Each signed certificate links to the lab's own verification page, so the report can be confirmed independently of us.

03Analytical identity

ARA-290, molecule by molecule.

Studied in tissue-repair, cell-migration and immune-signalling models in vitro.

CompoundEPO helix-B surface derived 11-amino-acid peptide
FormulaC51H84N16O21
Molecular weight1257.3 Da
Residues11
CAS1208243-50-8
FormLyophilised powder, 10 mg
StorageSealed at -20 °C, away from light and moisture

Sequence

11-residue chain. The full sequence and its mass-spec confirmation are on each lot certificate.

C51H84N16O211257.3 Da
Drag to turn
Residues · hover to locate11 residues
Heavy atoms
88
Bonds
88
Composition
C51 N16 O21
Rings
1
Metal centre
None
Chain length
11 residues

Every heavy atom is placed from the sequence with ideal bond lengths and angles, so the connectivity is exact. The pose is idealised (an extended chain) and is not a measured conformation. Identity for each lot is confirmed on its certificate.

Structure viewer

04In the lab

How ARA-290 is studied to work.

ARA-290 is built from the helix B surface of erythropoietin and does not bind the EPO receptor that drives red cell production. Laboratory studies tie it to the EPOR/beta common receptor tissue-protection complex and to Akt signaling.

Compound

ARA-290Helix B surface peptide derived from erythropoietin

  1. Wound repair

    Wound tissue

    • EPOR/beta-cR
    • Akt
    • eNOS

    Endpoint studied

    Wound closure

    Restored VEGF, phospho-Akt, phospho-eNOS and nitrite/nitrate in a diabetic wound model, with better closure.

    Bitto 2018 · PMID 29223734

  2. Cell survival

    Cardiomyocyte cell line

    • PI3K
    • Akt
    • mTOR

    Endpoint studied

    Less autophagy and death

    After hypoxia/reoxygenation: more viability, less apoptosis and LC3II; a PI3K inhibitor abolished this.

    Lin 2020 · PMID 32404595

  3. Mitochondria

    Cardiac myocytes

    • ROS
    • mPT

    Endpoint studied

    Oxidative stress tolerance

    Raised the ROS threshold for mitochondrial permeability transition (mPT) by 40%, similar to erythropoietin.

    Ahmet 2011 · PMID 21170473

Pathways as reported in the cited laboratory studies. For in-vitro research use only.

05Research history

7 years in the literature.

5 milestones, each linked to its PubMed record

  1. 2011

    Molecular Medicine

    Heart tissue protection

    The pyroglutamate helix B surface peptide, which does not bind the EPO receptor, matches EPO in protecting heart cells and limiting infarct size.

    PubMed · PMID 21170473
  2. 2011

    Anesthesiology

    The beta common receptor

    In a nerve injury model its effect depends on the beta common receptor, with none when that receptor is missing.

    PubMed · PMID 21873879
  3. 2013

    Experimental Biology and Medicine

    Kidney ischemia model

    Helix B surface peptide improves kidney function and cuts apoptosis after ischemia reperfusion, linked to PI3K/Akt signaling.

    PubMed · PMID 23479770
  4. 2016

    Shock

    Endothelial progenitors

    ARA290 raises proliferation, migration and oxidative stress resistance of endothelial colony-forming cells and their homing.

    PubMed · PMID 27172159
  5. 2018

    Biochimica et Biophysica Acta. Molecular Basis of Disease

    Diabetic wound repair

    Cibinetide restores VEGF, Akt and eNOS activity and improves closure and vessel growth in a diabetic wound model.

    PubMed · PMID 29223734 Latest

Laboratory research only, cited for research context. Not a claim about use in people.

06Questions

Frequently asked questions.

About ARA-290, its certificate and your order.

Need assistance? We’re here to help.

Email [email protected], Monday to Friday. A person replies within one business day.

Email supportContact page
01Which lot will I receive?

The current released lot, SA-ARA-2610. Scan the QR code on the vial label to open its certificate. The lot number is also on your packing slip, and the full certificate is here.

02Is the certificate real, and can I check it?

Every certificate is issued by an independent laboratory. Each lot has its own public record page with every assay value, and a link to verify the report on the lab's own site once the signed PDF is posted.

03Why does net content show more than 10 mg?

Vials are filled slightly over the labelled mass so that every vial meets it. Net content is measured on each lot and published as a number, not a pass.

04What if the vial arrives without vacuum or damaged?

Email [email protected] within 7 days with your order number and a photo and we will replace it.

05When will it ship?

Orders by 2 PM ET on a weekday ship the same day, with tracking emailed when the label prints.

06Is ARA-290 for human use?

No. It is sold strictly for in-vitro laboratory research and is not for human or animal use of any kind.

07Complete the box

Every vial counts toward your price.

3+ vials 25% off and 5+ vials 30% off across any mix, 10+ of one compound 40% off, 50+ of one compound 50% off.

Build a box
ARA-29010 mg · $60.00
1

View

Open full page

Certificate

Open lot record

Loading certificate